Neutrophil gelatinase-associated lipocalin: a biomarker in COPD.


BACKGROUND Neutrophil gelatinase-associated lipocalin (NGAL) is an antimicrobial peptide that could be involved in the pathogenesis of COPD. This study aimed to measure the plasma levels of NGAL in a large cohort of patients with COPD and control subjects and examine the levels of NGAL by COPD characteristics. METHODS The study included 402 patients with COPD and 229 control subjects aged 40 to 76 years from the Bergen COPD Cohort Study. All patients with COPD had an FEV(1)/FVC ratio of < 0.7, an FEV(1) < 80% predicted, and a smoking history of ≥ 10 pack-years. Plasma levels of NGAL were determined by enzyme immunoassay. Linear regression models were fitted with NGAL as the outcome variable. Confounders examined were sex, age, smoking, Charlson comorbidity score, use of inhaled steroids, neutrophil cell count, plasma creatinine and ferritin, and C-reactive protein. RESULTS Mean ± SD plasma concentrations of NGAL were 75.1 ± 31.8 ng/mL in patients with COPD and 56.5 ± 22.0 ng/mL in control subjects (P < .01). NGAL levels were bivariately associated with age, smoking, body composition, Charlson comorbidity score, neutrophil blood count, creatinine, and C-reactive protein but were significantly elevated in patients with COPD, even after adjustment for confounders. Frequent exacerbations and hypoxemia was associated with higher levels of NGAL, whereas increasing Global Initiative for Chronic Obstructive Lung Disease stage was associated with lower levels of NGAL among patients with COPD. CONCLUSIONS Plasma levels of NGAL were significantly higher in patients with COPD compared with control subjects. NGAL was related to important COPD characteristics.

DOI: 10.1378/chest.09-2718

8 Figures and Tables

Citations per Year

424 Citations

Semantic Scholar estimates that this publication has 424 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Eagan2010NeutrophilGL, title={Neutrophil gelatinase-associated lipocalin: a biomarker in COPD.}, author={Tomas Mikal Eagan and Jan K Dam{\aa}s and Thor Ueland and Marianne Voll-Aanerud and Tom Eirik Mollnes and Jon Andrew Hardie and Per S. Bakke and P{\aa}l Aukrust}, journal={Chest}, year={2010}, volume={138 4}, pages={888-95} }